Alternative splicing regulates activation-induced cytidine deaminase (AID): Implications for suppression of AID mutagenic activity in normal and malignant B cells

Blood

Volumn 112, Issue 12, 2008, Pages 4675-4682

  Wu, Xiaosheng ^a   Darce, Jaime R ^a   Chang, Sook Kyung ^a   Nowakowski, Grzegorz S ^b   Jelinek, Diane F ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; AICDA (ACTIVATION INDUCED CYTIDINE DEAMINASE); AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CANCER PATIENT; CELL LEVEL; CHRONIC LYMPHATIC LEUKEMIA; ENZYME ACTIVITY; ENZYME REPRESSION; GENE ACTIVATION; GENE INACTIVATION; GENE SWITCHING; GENETIC RECOMBINATION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; MEMORY CELL; MUTAGENIC ACTIVITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC HYPERMUTATION; ALTERNATIVE RNA SPLICING; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HELA CELL; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ALTERNATIVE SPLICING; ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; CONSERVED SEQUENCE; CYTIDINE DEAMINASE; ENZYME ACTIVATION; GERMINAL CENTER; HELA CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 58149384574     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-145995     Document Type: Article

References (53)

1. Peled JU, Kuang FL, Iglesias-Ussel MD, et al. The biochemistry of somatic hypermutation. Annu Rev Immunol. 2008;26:481-511.
2. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem. 2007;76:1-22.
3. Okazaki IM, Hiai H, Kakazu N, et al. Constitutive expression of AID leads to tumorigenesis. J Exp Med. 2003;197:1173-1181.
4. Wang CL, Harper RA, Wabl M. Genome-wide somatic hypermutation. Proc Natl Acad Sci U S A. 2004;101:7352-7356.
5. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
6. Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13:470-476.
7. Franco S, Gostissa M, Zha S, et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell. 2006; 21:201-214.
8. Ramiro AR, Jankovic M, Eisenreich T, et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004;118:431-438.
9. Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia. 2007;21:18-29.
10. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262.
11. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet. 2008;40:108-112.
12. Kotani A, Kakazu N, Tsuruyama T, et al. Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proc Natl Acad Sci U SA. 2007;104:1616-1620.
13. Albesiano E, Messmer BT, Damle RN, Allen SL, Rai KR, Chiorazzi N. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood. 2003; 102:3333-3339.
14. McCarthy H, Wierda WG, Barron LL, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood. 2003;101:4903-4908.
15. Oppezzo P, Vuillier F, Vasconcelos Y, et al. Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood. 2003;101:4029-4032.
16. Greeve J, Philipsen A, Krause K, et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood. 2003;101:3574-3580.
17. Babbage G, Garand R, Robillard N, Zojer N, Stevenson FK, Sahota SS. Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events. Blood. 2004;103:2795-2798.
18. Noguchi E, Shibasaki M, Inudou M, et al. Association between a new polymorphism in the activation-induced cytidine deaminase gene and atopic asthma and the regulation of total serum IgE levels. J Allergy Clin Immunol. 2001;108:382-386.
19. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553-563.
20. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
21. Van Parijs L, Refaeli Y, Lord JD, Nelson BH, Abbas AK, Baltimore D. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity. 1999;11:281-288.
22. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7:1063-1066.
23. Wu X, Platt JL, Cascalho M. Dimerization of MLH1 and PMS2 limits nuclear localization of MutLalpha. Mol Cell Biol. 2003;23:3320-3328.
24. Muramatsu M, Sankaranand VS, Anant S, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem. 1999;274:18470-18476.
25. Stamm S, Ben-Ari S, Rafalska I, et al. Function of alternative splicing. Gene. 2005;344:1-20.
26. Greiner A, Tobollik S, Buettner M, et al. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol. 2005;205:541-547.
27. Hentze MW, Kulozik AE. Aperfect message: RNA surveillance and nonsense-mediated decay. Cell. 1999;96:307-310.
28. Bachl J, Carlson C, Gray-Schopfer V, Dessing M, Olsson C. Increased transcription levels induce higher mutation rates in a hypermutating cell line. J Immunol. 2001;166:5051-5057.
29. Ito S, Nagaoka H, Shinkura R, et al. Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc Natl Acad Sci U SA. 2004;101:1975-1980.
30. Wu X, Geraldes P, Platt JL, Cascalho M. The double-edged sword of activation-induced cytidine deaminase. J Immunol. 2005;174:934-941.
31. McBride KM, Barreto V, Ramiro AR, Stavropoulos P, Nussenzweig MC. Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase. J Exp Med. 2004; 199:1235-1244.
32. Pasqualucci L, Guglielmino R, Houldsworth J, et al. Expression of the AID protein in normal and neoplastic B cells. Blood. 2004;104:3318-3325.
33. Hardianti MS, Tatsumi E, Syampurnawati M, et al. Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. Leukemia. 2004;18:826-831.
34. Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood. 2004;104:3312-3317.
35. Nilsen H, An Q, Lindahl T. Mutation frequencies and AID activation state in B-cell lymphomas from Ung-deficient mice. Oncogene. 2005;24:3063-3066.
36. Liu M, Duke JL, Richter DJ, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature. 2008;451:841-845.
37. Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature. 2006;440:105-109.
38. Nilsen H, Stamp G, Andersen S, et al. Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas. Oncogene. 2003;22:5381-5386.
39. Edelmann W, Yang K, UmarA, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell. 1997;91:467-477.
40. Reitmair AH, Schmits R, EwelA, et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet. 1995;11:64-70.
41. Campbell MR, Nation PN, Andrew SE.Alack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy. Cancer Res. 2005;65:2626-2635.
42. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432:635-639.
43. Wu X, Jelinek DF. A-Miz-ing BCL6. Nat Immunol. 2005;6:964-966.
44. Barreto V, Reina-San-Martin B, Ramiro AR, McBride KM, Nussenzweig MC. C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol Cell. 2003;12:501-508.
45. Zhu Y, Nonoyama S, Morio T, Muramatsu M, Honjo T, Mizutani S. Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J Med Dent Sci. 2003;50:41-46.
46. Chen KM, Harjes E, Gross PJ, et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature. 2008;452:116-119.
47. Heintel D, Kroemer E, Kienle D, et al. High expression of activation-induced cytidine deaminase (AID) mRNAis associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia. 2004;18:756-762.
48. Cheng C, Yaffe MB, Sharp PA.Apositive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev. 2006;20:1715-1720.
49. Katzenberger RJ, Marengo MS, Wassarman DA. ATM and ATR pathways signal alternative splicing of Drosophila TAF1 pre-mRNA in response to DNA damage. Mol Cell Biol. 2006;26:9256-9267.
50. Pelisch F, Blaustein M, Kornblihtt AR, Srebrow A. Cross-talk between signaling pathways regulates alternative splicing: a novel role for JNK. J Biol Chem. 2005;280:25461-25469.
51. Springer J, McGregor GP, Fink L, Fischer A. Alternative splicing in single cells dissected from complex tissues: separate expression of preprotachykinin A mRNA splice variants in sensory neurones. J Neurochem. 2003;85:882-888.
52. Kanumilli S, Tringham EW, Payne CE, Dupere JR, Venkateswarlu K, Usowicz MM. Alternative splicing generates a smaller assortment of CaV2.1 transcripts in cerebellar Purkinje cells than in the cerebellum. Physiol Genomics. 2006; 24:86-96.
53. Ou Y, Strege P, Miller SM, et al. Syntrophin gamma 2 regulates SCN5A gating by a PDZ domain-mediated interaction. J Biol Chem. 2003; 278:1915-1923.